Krystal Biotech, Inc.

KRYS · United States

Share price · KRYS

$315.34-17.48 (-5.25%) 3M

close as of 2026-11-18 · 24h delayed · vol 346K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when KRYS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+5.6%
  2. 2 Nov 2026-11.0%
  3. 30 Oct 2026+2.4%
  4. 3 Aug 2026-8.4%
  5. 27 Jul 2026+5.0%
  6. 14 Jul 2026-6.6%
  7. 4 May 2026+7.9%
  8. 2 Mar 2026-6.1%
  9. 19 Feb 2026-7.3%
  10. 20 Jan 2026-3.6%

Share of unusual movement by asset

For each asset, the share of KRYS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Beremagene geperpavec (Vyjuvek)
events and moves
7shown from 8 days
KB407
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—40%
Sessions with no dated event—57%

Assets

(4 total)
4Total Assets
1Approved
0Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
COL7A1 (type VII collagen gene replacement)Gene therapy / editing
Dystrophic Epidermolysis Bullosa
Phase 1/2
IL-12 / IL-2 (vector-encoded cytokines)Gene therapy / editing
Non-Small Cell Lung Cancer
Phase 1
CFTR (gene replacement)Gene therapy / editing
Cystic Fibrosis
Phase 1
SERPINA1 (alpha-1 antitrypsin; gene replacement)Gene therapy / editing
Alpha-1 Antitrypsin Deficiency

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
KB707Phase 1/2Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
Est. primary completion 2027-02 · NCT06228326 · CT.gov ↗
What to watch
July 2027 (1)
KB707Phase 1/2Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
Est. primary completion 2027-07 · NCT05970497 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

15 May 2026ApprovalBeremagene geperpavecMHRA grants UK marketing authorization for VYJUVEK
UK, MHRA · Source ↗
24 July 2025ApprovalBeremagene geperpavecVYJUVEK approved in Japan for DEB
JP, MHLW · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$127M$15M$463M+ $449M short-term inv.—$91M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$119M$15M$428M+ $418M short-term inv.—$75M operating cash flowreport ↗
2026-Q1$116M$15M$501M+ $322M short-term inv.—$80M operating cash flowreport ↗
2025-Q3$98M$15M$393M+ $338M short-term inv.—$40M operating cash flowreport ↗
2025-Q2$96M$14M$354M+ $328M short-term inv.—$53M operating cash flowreport ↗
2025-Q1$88M$14M$309M+ $308M short-term inv.—$31M operating cash flowreport ↗
2024-Q3$84M$14M$374M+ $214M short-term inv.—$59M operating cash flowreport ↗
2024-Q2$70M$16M$346M+ $214M short-term inv.—-$4.2M operating cash flowreport ↗
2024-Q1$45M$11M$359M+ $179M short-term inv.—$16M operating cash flowreport ↗
2023-Q3$8.6M$11M$373M+ $189M short-term inv.—-$21M operating cash flowreport ↗
2023-Q2$0$12M$276M+ $202M short-term inv.$33M-$34M operating cash flowreport ↗
2023-Q1$0$12M$141M+ $210M short-term inv.$45M-$26M operating cash flowreport ↗
2022-Q3$0$12M$186M+ $208M short-term inv.$30M-$20M operating cash flowreport ↗
2022-Q2—$11M$219M+ $207M short-term inv.$28M-$43M operating cash flowreport ↗
2022-Q1—$9.3M$269M+ $165M short-term inv.$50M-$15M operating cash flowreport ↗
2021-Q3—$6.1M$287M+ $56M short-term inv.$16M-$7.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$389M$58M$496M+ $331M short-term inv.—$201M operating cash flowreport ↗

For fiscal year 2025, Krystal Biotech reported revenue of $389.13M, up 33.9% YoY, with R&D spend of $58.05M, up 8.4% YoY. The company held cash and equivalents of $496.3M and reported net income of $204.83M.

The filing highlights VYJUVEK’s approvals in the U.S., EU, and Japan for dystrophic epidermolysis bullosa, with 2025 launches in Germany, France, and Japan and a U.S. label update expanding eligibility from birth and increasing dosing flexibility. Pipeline activity includes clinical-stage candidates such as KB407 for cystic fibrosis and programs in ophthalmology and dermatology, and the FDA granted platform technology designation to the HSV-1 vector used in KB801 for neurotrophic keratitis. Cumulative VYJUVEK net product revenue since launch was $730.3M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$291M$54M$345M+ $253M short-term inv.—$123M operating cash flowreport ↗
2023-FY$51M$46M$358M+ $174M short-term inv.—-$89M operating cash flowreport ↗
2022-FY$0$42M$162M+ $217M short-term inv.$35M-$101M operating cash flowreport ↗
2021-FY$0$28M$341M+ $97M short-term inv.$17M-$48M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 142 sales ($105.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12ROSSI DINO A · directorGift3,500——Form 4
2026-09-14ROSSI DINO A · directorAward / grant (derivative)1,187——Form 4
2026-09-14Gangolli Julian S · directorAward / grant (derivative)1,187——Form 4
2026-09-14JANNEY DANIEL · directorAward / grant (derivative)1,187——Form 4
2026-09-14Mason Christopher · directorAward / grant (derivative)1,187——Form 4
2026-09-14Mazzacco Catherine · directorAward / grant (derivative)1,187——Form 4
2026-09-14Sutherland Everett Rand · directorAward / grant (derivative)1,187——Form 4
2026-09-14ROSSI DINO A · directorAward / grant (derivative)471——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 365 reporting institutions held 28.4M shares ($7.1B).

#InstitutionSharesValue
1FMR LLC4,373,987$1.1B
2BlackRock, Inc.3,940,456$1.0B
3Avoro Capital Advisors LLC2,888,888$746.3M
4VANGUARD PORTFOLIO MANAGEMENT LLC1,456,727$376.3M
5STATE STREET CORP1,314,434$339.5M
6VANGUARD CAPITAL MANAGEMENT LLC1,165,324$301.0M
7Soleus Capital Management, L.P.1,153,087$297.9M
8Capital World Investors824,720$213.0M
9Redmile Group, LLC673,505$174.0M
10GEODE CAPITAL MANAGEMENT, LLC643,975$166.4M
11Hood River Capital Management LLC619,586$160.1M
12Bellevue Group AG481,785$124.5M
13Frazier Life Sciences Management, L.P.481,307$124.3M
14DIMENSIONAL FUND ADVISORS LP468,990$121.1M
15WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC407,178$105.2M